MX2024012369A - Terapia combinada para el tratamiento del cancer - Google Patents

Terapia combinada para el tratamiento del cancer

Info

Publication number
MX2024012369A
MX2024012369A MX2024012369A MX2024012369A MX2024012369A MX 2024012369 A MX2024012369 A MX 2024012369A MX 2024012369 A MX2024012369 A MX 2024012369A MX 2024012369 A MX2024012369 A MX 2024012369A MX 2024012369 A MX2024012369 A MX 2024012369A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
combination therapy
combination
azd5305
Prior art date
Application number
MX2024012369A
Other languages
English (en)
Spanish (es)
Inventor
Sabina Chiara Cosulich
BROWN Jessica S
Albertella Mark R
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024012369A publication Critical patent/MX2024012369A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MX2024012369A 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer MX2024012369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362614P 2022-04-07 2022-04-07
PCT/EP2023/059123 WO2023194525A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
MX2024012369A true MX2024012369A (es) 2024-11-08

Family

ID=86184958

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012369A MX2024012369A (es) 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20250228847A1 (enExample)
EP (1) EP4504147A1 (enExample)
JP (1) JP2025511403A (enExample)
KR (1) KR20240170958A (enExample)
CN (1) CN118973555A (enExample)
AU (1) AU2023250030A1 (enExample)
CA (1) CA3254950A1 (enExample)
IL (1) IL316019A (enExample)
MX (1) MX2024012369A (enExample)
TW (1) TW202404592A (enExample)
WO (1) WO2023194525A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
CN118973555A (zh) 2024-11-15
CA3254950A1 (en) 2023-10-12
KR20240170958A (ko) 2024-12-05
JP2025511403A (ja) 2025-04-15
AU2023250030A1 (en) 2024-11-07
EP4504147A1 (en) 2025-02-12
US20250228847A1 (en) 2025-07-17
TW202404592A (zh) 2024-02-01
IL316019A (en) 2024-11-01
WO2023194525A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
NI201900105A (es) Terapia combinada para el cáncer de próstata
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
ZA201907225B (en) Treatment of her2 positive cancers
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
MX2025003354A (es) Anticuerpos que se unen a 5t4
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
CO2021016982A2 (es) Métodos de uso de una construcción biespecífica de unión al antígeno dirigida a her2 para el tratamiento de cánceres de las vías biliares
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX2020003830A (es) Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
MX2024009923A (es) Metodos para tratar el cancer de prostata.